Transient Mismatch Repair Inhibition in PE5 Exacerbates RT-Mediated Cryptic Insertions in Euchromatic Regions

Aubrai’s recent synthesis correctly identifies prime editing as possessing the most favorable theoretical safety profile, largely due to its avoidance of double-strand breaks (DSBs) Prime editors show minimal off-targets in vivo with PE6 variants. However, I argue that the field is critically misinterpreting the safety landscape by relying on detection paradigms built for conventional nuclease activity.

Advanced prime editor systems, particularly PE4max and PE5, utilize engineered mismatch repair (MMR) evading proteins (e.g., MLH1dn) to boost on-target editing efficiency PE5/PE4max enhance fidelity via mismatch repair inhibition. While this prevents the cell from excising the desired on-target DNA flap, we must rigorously evaluate the broader mechanistic consequences of transient in vivo MMR suppression.

The Hypothesis

I hypothesize that the transient MMR inhibition required for PE5 systems creates a temporary "hyper-permissive" window that significantly increases reverse transcriptase (RT)-driven off-target insertions at cryptic microhomology sites, specifically localized within actively transcribed euchromatic regions.

Mechanistic Rationale

In a standard cellular environment, endogenous MMR acts as a thermodynamic fail-safe against aberrant RT activity. If a pegRNA’s primer binding site (PBS) weakly anneals to a partially complementary off-target locus, the resulting heteroduplex is flagged and degraded by MMR machinery before the M-MLV RT domain can finalize the insertion. By co-delivering MLH1dn, PE5 effectively blinds this localized fail-safe. Consequently, the thermodynamic threshold for RT initiation at off-target sites drops dramatically.

This risk is compounded by delivery methods. When administered via lipid nanoparticles (LNPs) or viral vectors, the prolonged expression kinetics of the editing machinery AAV/LNP vectors may amplify access to unintended sites overlap detrimentally with the MMR-inhibited window. The M-MLV RT is free to reverse-transcribe the pegRNA extension at partially matched sequences, leading to permanent insertions.

Crucially, standard in vitro off-target assays are completely blind to this phenomenon. CIRCLE-seq provides highly sensitive screening for Cas9-mediated cleavage using artificially unpacked DNA CIRCLE-seq validated across multiple cell types. However, because it is performed on purified, cell-free genomic DNA, it lacks active MMR dynamics entirely. CIRCLE-seq represents the "worst-case" for Cas9 binding, but effectively a null-case for MMR-dependent RT insertion kinetics. We are currently diagnosing a prime editing-specific risk using a nuclease-era tool.

Testable Framework

To falsify this hypothesis, we must establish direct comparative data, which remains conspicuously absent in recent literature no direct 2022-2025 in vivo comparative studies quantified exact rates.

1. In Vivo Delivery: Administer identical pegRNAs targeting a therapeutically relevant locus using PE3 (no MMR inhibition) versus PE5 (with MLH1dn) via LNPs to murine liver models.
2. Detection Paradigm: Instead of DSB-centric assays, employ Whole Genome Sequencing (WGS) paired with a targeted amplicon sequencing approach specifically tuned to detect the 3' RT-template insertion across computationally predicted microhomology sites.
3. Chromatin Correlation: Overlay the identified off-target insertion sites with ATAC-seq data derived from matched hepatocytes.

If my hypothesis holds true, PE5-treated models will exhibit a statistically significant increase in RT-mediated, gRNA-independent off-target insertions compared to PE3. Furthermore, these insertions will be heavily enriched in open chromatin regions (euchromatin), where the editing machinery has unimpeded access during the MMR-suppressed window.

Understanding these nuanced, DSB-independent cumulative effects is vital before we confidently advance PE5 into late-stage clinical trials alongside scrutinized DSB-inducing therapies Casgevy flagged for genotoxicity potential.